GPT Healthcare Share Price Analysis: Targets 2026–2030 and Fundamentals

GPT Healthcare share price today

Anyone searching the GPT Healthcare share price is looking at one of the smaller listed hospital operators in India: a Kolkata-based chain trading under the ILS Hospitals brand, with a market capitalisation of about ₹1,330 crore and roughly 2,124 employees. Hospitals are a business people instinctively like — demand is non-discretionary, pricing is sticky and the asset base is real. The complication here is that scale in hospitals is bought with capital, and this company is still small enough that a single new bed block changes the economics of the whole group.

At the 10 September 2026 close the stock was around ₹162, against a 52-week range of ₹115.31 to ₹170.49. That places it roughly 5% below its one-year high and about 40% above its one-year low. Trailing EPS was ₹5.82, book value per share ₹32.84, and the resulting multiples were about 27.8 times earnings and 4.9 times book. The quote above updates after publication; every ratio and scenario input below stays fixed to that close.

The tension worth holding on to is visible in three numbers from the same capture. Revenue grew 17.8% year on year and trailing profit is running ahead of the last reported full year, yet the audited profit for the year to March 2026 was lower than the two years before it. A hospital chain that is expanding capacity will show exactly that pattern. Whether the pattern ends in higher returns or merely higher depreciation is the entire question.

What GPT Healthcare actually runs

GPT Healthcare Limited owns and operates a chain of hospitals under the ILS Hospitals name. The company was incorporated in 1989, is based in Kolkata, and is described as a subsidiary of GPT Sons Pvt. Ltd. Alongside the hospitals it runs clinics and pharmacies and the ILS Agartala Nursing Institute. Yahoo Finance classifies it under Healthcare, industry Medical Care Facilities.

Service layer	What it covers	Why it matters economically
Multi-speciality inpatient care	Internal medicine and diabetology, critical care, paediatrics, gynaecology and obstetrics	Fills beds and drives occupancy, the core operating lever
Surgical specialities	Laparoscopic and general surgery, orthopaedics and joint replacement, neurosciences	Higher average revenue per occupied bed than medical admissions
High-acuity programmes	Nephrology with renal transplants, interventional cardiology, gastroenterology	Anchor specialities that build referral reputation
Clinics and pharmacies	Outpatient access points and in-house dispensing	Feeds inpatient volume and adds attached revenue
Nursing education	ILS Agartala Nursing Institute	Addresses the clinical-staffing constraint that limits bed expansion

That last line is not decoration. In Indian hospital operations the binding constraint is rarely land or equipment; it is doctors and trained nurses. An operator running its own nursing institute in Agartala is telling you where it expects to add beds and how it plans to staff them. The company’s own site sits at ilshospitals.com, which is also where the network’s locations and specialities are published.

What moves the GPT Healthcare share price

Three structural facts about this particular share matter more than the sector narrative. First, promoters hold 66.77%, leaving a free float of roughly a third of the equity. Second, there are about 8.21 crore shares outstanding in total, so the tradable pool is genuinely small. Third, profit is lumpy at this size — the year-on-year earnings growth figure captured on 10 September was 64.9%, which is not a rate any hospital chain sustains and is instead the mathematical consequence of comparing against a weak base.

A high promoter stake and a thin float cut both ways. It aligns the controlling shareholder with minority holders, and it means modest buying or selling can move the price further than the underlying news deserves. Anyone reading a single day’s move on this counter should assume liquidity is part of the explanation. The related question — how to size a position when the float is this thin — is a portfolio-construction problem, not a valuation one.

Revenue growth and the quarterly path captured to March 2026

The four most recent quarterly revenue rows captured from Yahoo Finance are set out below, using Yahoo’s own labels. Only revenue was captured for these quarters. There is no quarterly profit, margin or EPS series in the data behind this article, so none is stated or estimated anywhere in it.

Quarter (Yahoo label)	Revenue	Sequential reading
2Q2025	₹107 Cr	Base quarter of the captured series
3Q2025	₹119 Cr	Up sharply from the prior quarter
4Q2025	₹120 Cr	Broadly flat sequentially
1Q2026	₹126 Cr	Highest of the four

Those four quarters sum to about ₹472 crore, which lines up almost exactly with the ₹473 crore reported for the financial year ended March 2026. In other words, the captured series is that full year rather than the most recent four quarters. Trailing-twelve-month revenue at the September capture was ₹492 crore — higher than the ₹473 crore annual figure — which tells you at least one more recent quarter sits inside the trailing window without appearing in the table above. That gap is the honest limit of what this dataset can show about the current run-rate.

The direction within the year is still informative: revenue rose at every one of the three sequential steps — though the middle one only marginally — and finished about 18% above where it started. Reported revenue growth year on year at the capture date was 17.8%, consistent with that path.

FY24 to FY26: profit went backwards while revenue rose

The annual rows are labelled by the calendar year in which the March financial year ended, so 2026 means the year to March 2026. Across the two years for which revenue was captured, revenue was never the constraint; profit was.

Financial year ended	Revenue	Net profit	Reading
March 2024	Not captured	₹48 Cr	Profit base for the comparison
March 2025	₹407 Cr	₹50 Cr	Strongest reported profit of the three years
March 2026	₹473 Cr	₹42 Cr	Revenue up about 16%, profit down about 16%
Trailing twelve months to Sept 2026	₹492 Cr	Not a reported annual period	Profit margin of 9.61% on this revenue

One audited year of falling profit against rising revenue is the single most important fact in this file. Profit rose between March 2024 and March 2025, from ₹48 crore to ₹50 crore; it is the following year that broke the pattern, with revenue up roughly 16% while net profit fell from ₹50 crore to ₹42 crore. Only one year in the captured record shows that combination, which is why it is a signal to be watched rather than a trend already established. In a hospital business the usual culprits are new-facility ramp-up costs, higher depreciation on commissioned capacity, higher interest during expansion, and clinical-staff cost inflation running ahead of tariff increases. The data behind this article does not break out which of those applied, and no attempt is made here to guess.

What can be said with arithmetic is that the trailing position has recovered. Trailing EPS of ₹5.82 across about 8.21 crore shares implies a trailing profit pool near ₹48 crore, above the ₹42 crore reported for the year to March 2026 and back in line with the March 2024 level. The 9.61% trailing profit margin on ₹492 crore of revenue corroborates that. The recovery is real in the trailing numbers; it has not yet been confirmed by a full audited year.

Margins, returns and the capital behind them

Measure	Reading (10 September 2026 unless noted)	What it says
Total revenue (TTM)	₹492 Cr	Small relative to listed hospital majors
EBITDA	₹82 Cr	About 16.7% of revenue
Operating margin	13.71%	After depreciation, materially thinner than EBITDA
Net profit margin	9.61%	Roughly ₹48 Cr of trailing profit
ROCE (5 August 2026 capture)	19.94%	Respectable for an asset-heavy operator
EPS ÷ book value per share	₹5.82 ÷ ₹32.84, about 17.7%	A rough read on the return the equity base earns

Every figure in that table rests on the 10 September 2026 capture with one exception. No return-on-capital figure was captured on that date, so the ROCE row carries over the Screener-derived snapshot of 5 August 2026, and it is annotated as such wherever it appears in this article.

The spread between a 16.7% EBITDA margin and a 13.71% operating margin is the depreciation charge, and in a capacity-adding hospital chain that gap normally widens before it narrows. A ROCE of 19.94% is the most encouraging number in the set: it says the capital already deployed is earning a decent return, which is not automatic in this industry. If ROCE holds near 20% while beds are added, the expansion is creating value. If it drifts down as new capacity is commissioned, the market will re-rate the multiple long before the accounting catches up.

Note that a reported return-on-equity figure was not among the values captured for this article. The 17.7% in the table above is simply trailing EPS divided by book value per share, disclosed as such; the audited ratio it approximates is set out in the return on equity guide, and this rough version is not a substitute for it.

Balance sheet: modest leverage, real interest cost

Balance-sheet item	Reading	Interpretation
Total debt	₹91 Cr	Small in absolute terms
Total cash	₹47 Cr	Net debt therefore about ₹44 Cr
Debt to equity	33.84%	Roughly a third of equity, not stretched
Book value per share	₹32.84	Equity base near ₹270 Cr across 8.21 crore shares
Market capitalisation	₹1,330 Cr	Price to book of 4.94×

Net debt of about ₹44 crore against ₹82 crore of EBITDA is not a solvency question. It is, however, a reminder that hospital expansion is usually funded with a mix of internal accrual and borrowing, and that interest expense is one of the plausible explanations for the profit dip in the year to March 2026. A debt-to-equity ratio near 34% leaves room to borrow more; whether that room should be used depends on the return the next block of beds earns. The mechanics of reading that ratio properly, including why the equity denominator matters as much as the debt numerator, are covered in the debt-to-equity ratio guide.

Price to book of 4.94 times deserves a moment. For an asset-heavy business, paying nearly five times the accounting value of the assets means the market is paying for the operating franchise — occupancy, case mix, doctor relationships — rather than for bricks. That is a defensible thing to pay for, and it is also the part of the valuation that disappears fastest if occupancy or case mix deteriorates.

Ownership, dividend and the shape of the shareholder register

Promoters held 66.77% at the capture date. The dividend yield was 1.87%, which on a ₹162 price is roughly ₹3 a share, or a little over half of trailing EPS of ₹5.82. That is an unusually generous payout ratio for a company still adding capacity, and it is worth watching. A hospital operator that pays out half its earnings is either confident that expansion can be funded from the rest plus modest borrowing, or is prioritising the promoter’s cash needs. The data here cannot distinguish between the two.

Institutional holding — foreign and domestic — was not among the captured figures, so no split of the remaining third of the register is stated.

Valuation at the 10 September 2026 close

Valuation measure	Reading (10 September 2026 unless noted)	Interpretation
Close	₹162	Fixed research input, not a live quote
Market capitalisation	₹1,330 Cr	Micro-cap; liquidity and execution risk matter
Trailing EPS	₹5.82	Yahoo Finance trailing basis
Recalculated P/E	27.84×	Price divided by trailing EPS
Reported P/E	27.86×	Agrees with the recalculation
Book value per share	₹32.84	Implies price to book of 4.94×
ROCE (5 August 2026 capture)	19.94%	The strongest number in the set
Dividend yield	1.87%	Roughly ₹3 a share on the stated price
52-week range	₹115.31 – ₹170.49	Close sits about 5% below the high

Roughly 28 times trailing earnings is not obviously cheap for a micro-cap hospital chain, and it is not obviously expensive either. It is the multiple a market assigns when it believes earnings will normalise upward from a disappointing reported year. A separate set of Screener-derived figures captured on 5 August 2026 put the five-year sales CAGR at 14.25% and the five-year profit CAGR at 15.88%, and that same August capture is the sole source of the 19.94% ROCE quoted throughout this article. Those are the growth rates the current multiple is implicitly extrapolating. For a step-by-step account of how a trailing P/E should and should not be used, see the P/E ratio formula guide.

For context on how the same framework reads at the other end of the sector, the Apollo Hospitals analysis covers a national network with a very different cost of capital and bargaining position with payers.

Valuation framework: growth has to earn the multiple

The scenario model starts with TTM EPS of ₹5.82. For each year it applies EPS_TTM × (1 + growth)^(year − 2026 + 112/365) × exit P/E, then rounds the result to the nearest ₹5. The 112/365 factor represents the fraction of the first forecast year remaining from 10 September to 31 December. Dividends are excluded from the calculation.

Scenario	Annual EPS growth	Exit P/E	Business interpretation
Bear	8%	18×	Expansion costs persist, occupancy gains stall and the market re-rates a micro-cap hospital chain down toward book-plus
Base	13%	26×	Revenue keeps compounding in the mid-teens, the March 2026 profit dip proves temporary and ROCE holds near 20%
Bull	18%	33×	New capacity fills quickly, case mix shifts toward high-acuity work and margins move toward the sector’s better operators

The growth rates are deliberately set below the 15.88% five-year profit CAGR at the bear and base ends, because a company that has just reported a profit decline has not earned the right to have its strongest historical rate extrapolated. The multiple range is anchored below-to-modestly-above the present 27.8 times. Assuming both flawless growth and permanent multiple expansion would simply restate today’s optimism as arithmetic. These are scenarios, not probability-weighted forecasts. The general method sits in how to value a stock.

GPT Healthcare share price target 2026 to 2030

The grid above is generated purely from the disclosed trailing EPS, the three growth rates and the three exit multiples. It does not model a fresh equity issue, an acquisition of another hospital, a change in the dividend policy, a regulatory tariff change, exceptional items or any shift in the capital structure. It also cannot model the thing that matters most for a hospital operator — the ramp curve of newly commissioned beds — because that curve is not in the data. Treat it as a way of seeing how sensitive the outcome is to the two inputs, and refresh both inputs after the next audited year.

Risks that can break the thesis

The first risk is the one already visible: profit fell in the year to March 2026 even as revenue rose 16%. If that repeats, the trailing recovery implied by ₹5.82 of EPS was a blip rather than a turn, and roughly 28 times earnings becomes very hard to defend.

The second is concentration. This is a regional chain built around Kolkata and the east, not a national network. Regional exposure means a local competitive entry, a state tariff decision or a single facility’s problems carry more weight than they would in a diversified operator. The third is clinical-staff cost inflation: doctor and nurse compensation in India has been rising faster than realisation per bed for several years, which is precisely the squeeze that shows up as a widening gap between EBITDA and operating margins.

The fourth is liquidity and float. With promoters at 66.77% and a market capitalisation near ₹1,330 crore, price discovery is thin. The fifth is the payout: distributing a little over half of trailing earnings while adding capacity leaves less internal funding, and closing that gap with debt would lift the 33.84% debt-to-equity ratio at exactly the moment new assets are not yet earning. Finally, any adverse clinical or regulatory event at a hospital damages reputation and referral flow faster than it damages the accounts.

What would change the picture

The constructive evidence would be an audited year in which revenue growth in the mid-teens is accompanied by profit growth at least as fast, ROCE held at or above 20%, and the operating margin moving up rather than down as commissioned capacity matures. Disclosure of occupancy, average revenue per occupied bed and average length of stay would materially improve the quality of any analysis of this company, because those three numbers explain hospital economics better than any consolidated ratio does.

The case weakens if revenue growth continues to outrun profit growth for a second year, if debt rises materially while ROCE falls, if the dividend is maintained by borrowing rather than by earnings, or if the eastern-India competitive position erodes. A general framework for reading each result release against these markers is set out in how to read quarterly results.

Monitoring scorecard

Question	Constructive evidence	Warning sign
Is profit following revenue?	Net profit grows at least as fast as the mid-teens revenue rate	A second consecutive year of rising sales and falling profit
Is new capacity earning?	ROCE holds at or above 19.94%	ROCE falls as fixed assets rise
Are margins holding?	Operating margin moves above 13.71%	Gap between EBITDA and operating margin keeps widening
Is leverage controlled?	Debt to equity stays near or below 33.84%	Borrowing rises to fund both capex and the dividend
Is the payout sustainable?	Dividend covered comfortably by earnings after capex	Payout ratio rises above half of EPS
Is the franchise intact?	Case mix shifts toward high-acuity specialities	Occupancy or referral flow deteriorates in core hospitals

What to weigh at the current price

GPT Healthcare is a small, profitable, promoter-controlled hospital chain earning a near-20% return on capital, carrying modest net debt of about ₹44 crore, and paying a 1.87% dividend. Those are not the characteristics of a speculative micro-cap. The five-year record — 14.25% sales CAGR and 15.88% profit CAGR — describes a business that has compounded steadily rather than spectacularly.

Set against that, the most recent audited year showed profit going backwards while revenue advanced, the price sits near the top of its 52-week range at about 28 times trailing earnings and nearly five times book, and the free float is small enough that the quoted price is a noisier signal than usual. The evidence that would settle the argument is not another expansion announcement. It is one audited year in which the beds already built show up as profit.

FAQ

What is GPT Healthcare’s share price target for 2026?

The 2026 scenario is computed from trailing EPS of ₹5.82 grown for the fraction of the year remaining after 10 September, then multiplied by each scenario’s exit P/E. Because only about four months of 2026 remain from the research cut-off, the 2026 figures are driven far more by the choice of multiple than by the growth rate. They are illustrations of a range, not forecasts.

What is GPT Healthcare’s share price target for 2030?

The 2030 scenarios apply the same trailing EPS compounded at 8%, 13% and 18% a year and capitalised at 18, 26 and 33 times respectively. Four years of compounding makes the outcome extremely sensitive to both inputs, so the spread between the low and high cases is wide by design. Neither end should be read as a prediction.

What does GPT Healthcare do?

It owns and operates a chain of hospitals under the ILS Hospitals brand, together with clinics, pharmacies and the ILS Agartala Nursing Institute. The specialities span internal medicine and diabetology, nephrology with renal transplants, laparoscopic and general surgery, critical care, paediatrics, gastroenterology, gynaecology and obstetrics, interventional cardiology, orthopaedics and joint replacement, and neurosciences. It was incorporated in 1989 and is based in Kolkata.

Who are the promoters of GPT Healthcare?

Promoter holding stood at 66.77% at the 10 September 2026 capture. Yahoo Finance describes the company as a subsidiary of GPT Sons Pvt. Ltd. That leaves a free float of roughly a third of the equity, which is one reason the share can move sharply on modest volume.

What is the ROCE of GPT Healthcare?

Return on capital employed was 19.94%, from the Screener-derived figures captured on 5 August 2026. No return-on-capital figure was captured on 10 September, so this is the one number here that is a month older than the rest. For an asset-heavy hospital operator that is a solid number, and holding it near 20% while adding beds is the clearest single test of whether the expansion is working.

Why is GPT Healthcare’s share price falling?

At the 10 September 2026 close the share was not materially down: at ₹162 it sat about 5% below its 52-week high of ₹170.49 and roughly 40% above its 52-week low of ₹115.31. Day-to-day weakness on a counter with a free float of about a third often reflects thin liquidity rather than news. The genuine fundamental concern is different — net profit for the year to March 2026 fell to ₹42 crore from ₹50 crore, even though revenue rose to ₹473 crore.

Related research

• Apollo Hospitals share price target
• How to value a stock
• P/E ratio formula and how to use it
• Debt-to-equity ratio explained
• Return on equity (ROE)
• How to read quarterly results

Sources and methodology

• GPT Healthcare on Screener.in
• GPT Healthcare quote and filings on NSE
• GPT Healthcare company website

Price, 52-week range, market capitalisation, trailing EPS, book value, the P/E and price-to-book multiples, dividend yield, debt, cash, revenue, EBITDA, margins, promoter holding, share count and the annual and quarterly rows were all captured on 10 September 2026 from Yahoo Finance, after the completed session. The five-year sales CAGR of 14.25%, the five-year profit CAGR of 15.88% and the ROCE of 19.94% come from Screener-derived figures captured on 5 August 2026.

One limitation should be stated plainly: no full Screener financial table was captured for this company, so the multi-year revenue and profit history here rests on the Yahoo annual rows and the two CAGRs above rather than on a complete statement series. The quarterly rows carry revenue only — there is no quarterly profit, margin or EPS in the data — so no quarterly earnings figures appear anywhere in this article, and none have been estimated. A reported return-on-equity figure was likewise not captured; the 17.7% shown is trailing EPS divided by book value per share and is labelled as such.

Company description, specialities, employee count, incorporation year and ownership structure come from Yahoo Finance’s company profile and the company website. Everything beyond those figures — the reading of the profit decline, the interpretation of the EBITDA-to-operating-margin gap, the choice of growth rates and exit multiples, and the risk assessment — is analytical judgment, and should be treated as one reading of the evidence rather than the only one.

---

This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. The scenarios are illustrations, not guarantees. Verify current exchange filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.